Work

Abstract PS3-11-17: Pyrotinib as Continued Consolidation Therapy After Anti-HER2 Adjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer: A Multicenter Exploratory Study

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps3-11-17

Authors: T. Xia, J. Zhang, L. Xu, C. Yao, H. Yu, D. Wei, X. Lu, L. Wang, Z. Guo, Q. Fang, D. Fu, Q. Hu, K. Tan, K. Luo, H. Pan, X. Liu

Institutions: Jiangsu Province Hospital, Nanjing Medical University, Nanjing University of Chinese Medicine, Jiangsu University, Affiliated Hospital of Jiangsu University, Jiangsu Cancer Hospital, Soochow University, The First People's Hospital of Changzhou, First Affiliated Hospital of Soochow University, Northern Jiangsu People's Hospital, Yangzhou University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129613673

Cites:

Cited by:

Related to: